BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chew HY, Chan V, Simpson F, Dolcetti R. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit? Cancers (Basel) 2020;12:E3392. [PMID: 33207697 DOI: 10.3390/cancers12113392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 van Oost S, Meijer DM, Kuijjer ML, Bovée JVMG, de Miranda NFCC. Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger? Biomedicines 2021;9:1048. [PMID: 34440251 DOI: 10.3390/biomedicines9081048] [Reference Citation Analysis]
2 M. Gordon E, L. Angel N, T. Kim T, A. Brigham D, P. Chawla S, L. Hall F. Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy. Advances in Precision Medicine Oncology 2021. [DOI: 10.5772/intechopen.96664] [Reference Citation Analysis]
3 Gazouli I, Kyriazoglou A, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, Chatzidakis I, Kavourakis G, Economopoulou P, Kontogeorgakos V, Papagelopoulos P, Psyrri A. Systematic Review of Recurrent Osteosarcoma Systemic Therapy. Cancers (Basel) 2021;13:1757. [PMID: 33917001 DOI: 10.3390/cancers13081757] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]